Literature DB >> 15234817

Inhibition of NF-kappaB mediated inflammation by siRNA expressed by recombinant adeno-associated virus.

Olaf Pinkenburg1, Juliane Platz, Christoph Beisswenger, Claus Vogelmeier, Robert Bals.   

Abstract

NF-kappaB mediated inflammation is a key process to many diseases. RNA interference (RNAi) is the specific suppression of genes by short double-stranded RNA. It was the aim of the present study to modify NF-kappaBdependent inflammation by small interfering RNA (siRNA) expressed by recombinant adeno-associated virus (rAAV). To study the kinetics of rAAV mediated expression of siRNA, the expression of the luciferase gene was targeted and resulted in a significant decrease of luciferase activity as compared to a control vector in the human 293 cell line. The effect was dose dependent and was detectable 24 h after infection. rAAV coding for siRNA against the p65 subunit of NF-kappaBsignificantly reduced the p65 protein. In a cellular model of TNF-alpha induced inflammation, expression of siRNA against p65 significantly suppressed the secretion of IL-8 from BEAS-2B cells. In conclusion, rAAV vectors coding for siRNA are an useful tool for efficient gene silencing in mammalian cells and can be used to modify NF-kappaB mediated inflammation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15234817     DOI: 10.1016/j.jviromet.2004.04.007

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  11 in total

1.  High doses of siRNAs induce eri-1 and adar-1 gene expression and reduce the efficiency of RNA interference in the mouse.

Authors:  Jie Hong; Zhikang Qian; Shuiyuan Shen; Taishan Min; Chang Tan; JianFeng Xu; Yingchun Zhao; Weida Huang
Journal:  Biochem J       Date:  2005-09-15       Impact factor: 3.857

Review 2.  AAV hybrid serotypes: improved vectors for gene delivery.

Authors:  Vivian W Choi; Douglas M McCarty; R Jude Samulski
Journal:  Curr Gene Ther       Date:  2005-06       Impact factor: 4.391

Review 3.  RNA interference for improving the outcome of islet transplantation.

Authors:  Feng Li; Ram I Mahato
Journal:  Adv Drug Deliv Rev       Date:  2010-12-13       Impact factor: 15.470

4.  RNA interference targeting virion core protein ORF095 inhibits Goatpox virus replication in Vero cells.

Authors:  Zhixun Zhao; Guohua Wu; Xueliang Zhu; Xinmin Yan; Yongxi Dou; Jian Li; Haixia Zhu; Qiang Zhang; Xuepeng Cai
Journal:  Virol J       Date:  2012-02-17       Impact factor: 4.099

Review 5.  New therapeutics targets in chronic viral cardiomyopathy.

Authors:  W Poller; H Fechner; U Kühl; M Pauschinger; H P Schultheiss
Journal:  Ernst Schering Res Found Workshop       Date:  2006

Review 6.  Silencing viruses by RNA interference.

Authors:  Florence Colbère-Garapin; Bruno Blondel; Aure Saulnier; Isabelle Pelletier; Karine Labadie
Journal:  Microbes Infect       Date:  2005-03-13       Impact factor: 2.700

Review 7.  Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer.

Authors:  Sander W Tas; Margriet J B M Vervoordeldonk; Paul P Tak
Journal:  Curr Gene Ther       Date:  2009-06       Impact factor: 4.391

8.  Galangin Abrogates Ovalbumin-Induced Airway Inflammation via Negative Regulation of NF-κB.

Authors:  Wang-Jian Zha; Yan Qian; Yi Shen; Qiang Du; Fei-Fei Chen; Zhen-Zhen Wu; Xiao Li; Mao Huang
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-25       Impact factor: 2.629

9.  Effect of reactive oxygen species generation in rabbit corneal epithelial cells on inflammatory and apoptotic signaling pathways in the presence of high osmotic pressure.

Authors:  Yihui Chen; Min Li; Bing Li; Weifang Wang; Anjuan Lin; Minjie Sheng
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

Review 10.  Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease.

Authors:  Michael R Edwards; Nathan W Bartlett; Deborah Clarke; Mark Birrell; Maria Belvisi; Sebastian L Johnston
Journal:  Pharmacol Ther       Date:  2008-10-06       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.